Hims & Hers Health (NYSE:HIMS) Stock Price Target Lowered at Bank of America

Hims & Hers Health logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Bank of America lowered its Hims & Hers price target from $26 to $21 and maintained a neutral rating; the new target implies 41.65% upside from the share price cited in the report.
  • Hims & Hers reported quarterly EPS of $0.03, below the $0.06 consensus, and revenue of $890.37 million, slightly below estimates, despite revenue rising 48.6% year over year.
  • Shares fell 7.5% on Friday to $14.82. Across analysts, the stock has a consensus “Hold” rating and an average price target of $30.80.
  • Five stocks to consider instead of Hims & Hers Health.

Hims & Hers Health (NYSE:HIMS - Get Free Report) had its target price reduced by research analysts at Bank of America from $26.00 to $21.00 in a report released on Friday, Benzinga reports. The firm presently has a "neutral" rating on the stock. Bank of America's price target would indicate a potential upside of 41.65% from the stock's current price.

HIMS has been the subject of a number of other reports. Weiss Ratings reiterated a "sell (d)" rating on shares of Hims & Hers Health in a report on Wednesday, November 4th. Wall Street Zen raised Hims & Hers Health from a "sell" rating to a "hold" rating in a research note on Saturday, August 15th. Jefferies Financial Group decreased their price objective on shares of Hims & Hers Health from $31.00 to $24.00 and set a "hold" rating for the company in a report on Tuesday, November 10th. Morgan Stanley dropped their target price on shares of Hims & Hers Health from $28.00 to $25.00 and set an "equal weight" rating on the stock in a report on Tuesday, November 10th. Finally, Citigroup cut their target price on shares of Hims & Hers Health from $35.00 to $33.00 and set a "neutral" rating for the company in a research note on Tuesday, August 11th. Three equities research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, Hims & Hers Health presently has an average rating of "Hold" and a consensus price target of $30.80.

Read Our Latest Stock Report on HIMS

Hims & Hers Health Stock Down 7.5%

Shares of NYSE HIMS traded down $1.20 during midday trading on Friday, reaching $14.82. 7,785,157 shares of the company's stock were exchanged, compared to its average volume of 22,066,672. The company has a debt-to-equity ratio of 3.85, a quick ratio of 0.84 and a current ratio of 0.92. Hims & Hers Health has a 52-week low of $13.74 and a 52-week high of $40.99. The business's fifty day moving average price is $26.77 and its two-hundred day moving average price is $26.49. The stock has a market capitalization of $3.48 billion, a PE ratio of -17.89 and a beta of 2.53.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its quarterly earnings data on Monday, November 9th. The company reported $0.03 earnings per share for the quarter, missing analysts' consensus estimates of $0.06 by ($0.03). The business had revenue of $890.37 million for the quarter, compared to analyst estimates of $893.13 million. Hims & Hers Health had a negative net margin of 6.65% and a negative return on equity of 9.62%. Hims & Hers Health's revenue for the quarter was up 48.6% compared to the same quarter last year. During the same quarter last year, the business earned $0.06 EPS. Analysts forecast that Hims & Hers Health will post -0.38 EPS for the current year.

Insider Transactions at Hims & Hers Health

In other news, CFO Oluyemi Okupe sold 3,518 shares of the stock in a transaction on Tuesday, November 17th. The shares were sold at an average price of $18.53, for a total transaction of $65,188.54. Following the transaction, the chief financial officer owned 266,188 shares in the company, valued at $4,932,463.64. This represents a 1.30% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Deborah M. Autor sold 23,828 shares of the firm's stock in a transaction dated Tuesday, November 17th. The shares were sold at an average price of $18.53, for a total value of $441,532.84. Following the transaction, the insider owned 48,961 shares in the company, valued at approximately $907,247.33. This trade represents a 32.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 105,041 shares of company stock worth $2,764,840 in the last ninety days. Company insiders own 11.76% of the company's stock.

Institutional Trading of Hims & Hers Health

Several large investors have recently modified their holdings of the company. Bank of America Corp DE boosted its stake in Hims & Hers Health by 194.4% during the 1st quarter. Bank of America Corp DE now owns 4,357,672 shares of the company's stock valued at $90,465,000 after purchasing an additional 2,877,550 shares during the period. Bank of New York Mellon Corp bought a new stake in Hims & Hers Health in the 2nd quarter valued at $46,220,000. Bienville Capital Management LLC bought a new position in Hims & Hers Health during the second quarter valued at about $27,242,000. Southpoint Capital Advisors LP bought a new stake in shares of Hims & Hers Health during the first quarter valued at approximately $10,380,000. Finally, Swiss National Bank raised its stake in shares of Hims & Hers Health by 1.1% in the 1st quarter. Swiss National Bank now owns 390,500 shares of the company's stock valued at $8,107,000 after buying an additional 4,300 shares in the last quarter. 63.52% of the stock is owned by institutional investors.

About Hims & Hers Health

(Get Free Report)

Hims & Hers Health, Inc. operates a consumer-focused telehealth platform that connects patients with licensed healthcare providers and offers access to treatments and wellness products. Its services include online consultations, prescription care and over-the-counter products. The company serves a range of health needs, including hair loss, sexual health, skin care, mental health and weight management. Its platform also offers primary care and other services, with offerings varying by location and individual eligibility.

Further Reading

Analyst Recommendations for Hims & Hers Health (NYSE:HIMS)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Hims & Hers Health Right Now?

Before you consider Hims & Hers Health, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hims & Hers Health wasn't on the list.

While Hims & Hers Health currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines